In this episode, we tackle the recent papers in the New England Journal of Medicine on "Elotuzumab plus Pomalidomide and Dexamethasone for Multiple Myeloma" and "Immunotherapy Combinations in Multiple Myeloma", as well as a comment in The Lancet Oncology's editorial "9 Weeks That Matter for Patients With Gastric Cancer". We conclude with an interview with Dr. Erick Turner of OHSU on the FDA, regulatory capture, selective reporting, and transparency.Elo-pom-dex: http://doi.org/10.1056/NEJMoa1805762Immunotherapy combinations: http://doi.org/10.1056/NEJMp18036029 weeks that matter: http://doi.org/10.1016/S1470-2045(18)30752-6Dr. Turner's seminal paper: https://doi.org/10.1056/NEJMsa065779